Avenzo Therapeutics Announces $60 Million Series B Financing to support pipeline advancement of oncology drug candidates September 23, 2025
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant September 23, 2025
Pidnarulex (CX-5461) + Cemiplimab (Libtayo®) combo to be tested in Ph 1/2 clinical trial for MSS CRC patients September 23, 2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer September 23, 2025
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti September 23, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked ADC September 23, 2025
Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer September 16, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
Radiance Biopharma signs Exclusive License Agreement with Novatim Immune Therapeutics for RB-601™ (KY-0301), the c-MET/EGFR-targeting ADC September 10, 2025
Silexion Therapeutics Announces Selection of CRO to Support Upcoming Ph 2/3 Clinical Trials for SIL204 September 10, 2025
CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value September 9, 2025
TREOS Bio, Charité Berlin, and Junshi Biosciences to Launch Pivotal Ph 2 Trial of PolyPEPI1018, toripalimab, and SoC combo in Refractory MSS CRC September 3, 2025
CHARM Therapeutics raises $80M in Series B financing to advance development of menin inhibitor for AML September 3, 2025
Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US September 3, 2025
Accro Bioscience and Fosun Pharma Announce Exclusive License Agreement for AC-201 in Greater China September 3, 2025
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer September 3, 2025
Incyclix Bio Secures $11.25M Series B Extension for Ph 1/2 Trial of INX-315 in CDK4/6i-Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors August 26, 2025
